Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABNCoV2 vs Comirnaty Booster in Adults
NCT05329220Phase 3Completed
- Sponsor
- Bavarian Nordic
- Start
- Aug 2022
- Primary completion
- Mar 2023
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Peptide-based Cancer Vaccines
- Countries
- 3
01
Overview
A Phase 3 trial of abncov2 in coronavirus disease 2019 (COVID-19), sponsored by Bavarian Nordic. Started Aug 2022; status: completed.
02
Drugs
abncov2
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05329220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05329220.